Scrip's Complete Guide to CNS Disorders

Scrip's Complete Guide to CNS Disorders

Therapeutic

A comprehensive overview of the global market for current and forthcoming CNS drugs, this report covers the major areas: Alzheimer's disease, Parkinson's disease, depression, schizophrenia and anxiety. Six volumes supply you with invaluable information on CNS drugs in R&D and the global market for CNS therapies.

Access:

Extensive R&D information on over 150 products in clinical trials for CNS disorders
R&D details for over 200 drugs in preclinical research
Relative market share of products and sales forecasts to 2002 for each disease
18 top company profiles
Sales figures for the top 30 CNS drugs currently on the market

Each major disease area is covered in a separate volume containing definitions, pathogenesis, risk factors and epidemiology. The report also supplies descriptions of current treatments and information on their advantages and disadvantages.

Profiles of the 18 companies most active in the CNS field allow you to undertake accurate competitor analysis - and evaluate opportunities for strategic collaborations.

PUBLISHED: AUGUST 1999
REF: BS1023E
PAGES: 600+
PRICE: Complete six-volume set �990/$1,995/�238,000

For more information or details on individual volume pricing, please contact our Customer Helpdesk:
Tel +44 (0)20 8332 8965/66
Fax +44 (0)20 8332 8992

CONTENTS
LIST OF TABLES
ACKNOWLEDGEMENTS
EXECUTIVE SUMMARY
METHODOLOGY
ABBREVIATIONS
GLOSSARY

CHAPTER 1 INTRODUCTION TO SCHIZOPHRENIA AND OTHER PSYCHOSES
1.1 Background to schizophrenia
1.2 Definition of schizophrenia
1.3 Pathogenesis
1.3.1 What effect does the disease have?
1.4 Symptoms
1.4.1 Depression associated with schizophrenia
1.5 Opportunities for drug intervention
1.6 Aetiology
1.6.1 Risk factors
1.6.1.1 Genetic
1.6.1.2 Environment
1.6.1.3 Brain structure
1.6.1.4 Problems during pregnancy
1.6.1.5 Problems during birth
1.6.1.6 Substance misuse
1.6.1.7 Other theories
1.7 Epidemiology
1.7.1 Incidence and prevalence
1.8 Prognosis
1.9 Other psychoses
1.9.1 Background
1.10 Trends in treatment for schizophrenia and other psychoses
1.10.1 Problems with side effects
1.10.2 Method of administration
1.10.3 Treatments other than drug therapy

CHAPTER 2 MARKETED DRUGS
2.1 Summary of drug classes
2.2 Typical antipsychotics
2.2.1 Chlorpromazine
2.2.2 Haloperidol
2.3 Atypical antipsychotics
2.3.1 Atypical antipsychotics with dopaminergic and serotonergic activity
2.3.1.1 Amisulpride
2.3.1.2 Clozapine
2.3.1.3 Olanzapine
2.3.1.4 Quetiapine
2.3.1.5 Risperidone
2.3.1.6 Sertindole
2.3.1.7 Zotepine
2.4 Opportunities for new drugs

CHAPTER 3 DRUGS IN DEVELOPMENT
3.1 Antipsychotics in the R&D pipeline
3.2 Typical antipsychotics
3.2.1 (S)-amisulpride
3.2.2 Aripiprazole
3.3 Atypical antipsychotics with dopaminergic and serotonergic activity
3.3.1 Belaperidone
3.3.2 Blonanserin
3.3.3 BTS-79018
3.3.4 Iloperidone
3.3.5 Mazapertine succinate
3.3.6 Olanzapine
3.3.7 Org-5222
3.3.8 Perospirone
3.3.9 Quetiapine
3.3.10 Sarizotan hydrochloride
3.3.11 Talipexole
3.3.12 Ziprasidone
3.4 Atypical antipsychotics with serotonergic activity only
3.4.1 M-100907
3.4.2 SR-46349
3.5 Atypical antipsychotics with other activities
3.5.1 CEE 03-310
3.5.2 LU-201640
3.5.3 Mecamylamine
3.5.4 MS-355
3.5.5 NE-100
3.5.6 NGD 94-1
3.5.7 Osanetant
3.5.8 SC-111
3.5.9 Sonepiprazole
3.5.10 SR-141716
3.5.11 SR-27897
3.5.12 SR-31742
3.5.13 SR-48692
3.6 AMPAkines
3.6.1 AMPAlex
3.6.2 CX691
3.7 Miscellaneous
3.7.1 E-5842
3.7.2 LX-101a
3.7.3 Pramipexole
3.7.4 Prochlorperazine maleate
3.8 Research with potential for success

REFERENCES

LIST OF TABLES
Table 1.1 Incidence and prevalence of schizophrenia for different regions worldwide, 1995
Table 1.2 Worldwide incidence and prevalence data for areas with estimated levels of development, 1995
Table 1.3 Worldwide incidence and prevalence figures for schizophrenia in men and women, 1995
Table 1.4 Worldwide incidence and prevalence figures for schizophrenia in different age groups, 1995

Table 2.1 Summary of antipsychotic drugs on the market
Table 2.2 Summary of companies marketing antipsychotics for the treatment of schizophrenia

Table 3.1 Summary of registered antipsychotics
Table 3.2 Summary of antipsychotic drugs in clinical development for schizophrenia
Table 3.3 Summary of drugs in clinical development as antipsychotics that are not antipsychotics as a first indication
Table 3.4 Summary of antipsychotic drugs in preclinical development

This volume, Schizophrenia and Other Psychoses, is part of a series forming Scrip's Complete Guide to CNS Disorders. The other volumes in this series are:
Volume 1: Market Overview (BS1024)
Volume 2: Alzheimer's Disease and Other Dementias (BS1025)
Volume 3: Parkinson's Disease (BS1026)
Volume 4: Depression and Bipolar Disorder (BS1027)
Volume 6: Anxiety (BS1029)

EXECUTIVE SUMMARY
With 1% of the world's population suffering from schizophrenia at any one time, and $40 billion per annum spent on US healthcare associated with schizophrenia alone, the disorder is costly both in terms of drugs and hospital care. Furthermore, it is a major contributor to the suicide rate. The potential for successful drugs to reduce time spent in hospital and therefore reduce overall costs is enormous. The worldwide market for schizophrenia was approximately $2.2 billion in 1997 and is predicted to reach $6.1 billion in 2002, primarily because of switching from generics to newer compounds.

The market is currently torn between the older, well established and less costly 'typical' antipsychotics, such as haloperidol, and the newer, expensive 'atypical' antipsychotics which claim to have less severe side effects leading to an improved quality of life for patients. Patients stabilised on older compounds may remain on them. However, the newer compounds offer advantages which could significantly improve the lives of some patients by treating the more troublesome negative symptoms of the disorder as well as the positive ones.

The market for antipsychotics is on the verge of transition and more head-to-head studies and increased patient awareness of these reduced side effects will help determine whether the newer compounds really outsell the generics. Moreover, there are advances in understanding the causes of schizophrenia, and opportunities for improved drug development will undoubtedly arise from these findings. The issue of patient compliance is central and the demand for better dosing regimens, such as one dose per day, and longer-acting formulations, such as depot injection, is evident. This is because, although the majority of patients successfully respond to antipsychotics, many stop taking them and therefore relapse.

There is also potential for novel compounds and strategies that could benefit the 10-30% of patients who do not respond to medication, regardless of the dose.